Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Product comparison
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

2 evidence topics · 4 sources

Related immunotherapy combinations: LEAP-017, lenvatinib plus pembrolizumab versus standard of care

“there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC.” (opens the source at this quote in a new tab)

Related immunotherapy combinations: IMblaze370, atezolizumab with or without cobimetinib versus regorafenib

“IMblaze370 did not meet its primary endpoint of improved overall survival” (opens the source at this quote in a new tab)